Literature DB >> 18825743

Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.

Katja Mueller1, Oliver Schweier, Hanspeter Pircher.   

Abstract

We determined the efficacy of in vitro expanded P14 TCR transgenic CD8 T cells to mediate tumor cell elimination and to protect against viral infection in mice. Contrary to previous studies, an adoptive transfer model without lymphodepletion, vaccination or cytokine treatment was used. Antigen-activated P14 T cells cultured in IL-2-containing medium for 7 days (P14IL-2) exhibited potent effector cell functions in vitro but did not confer protection against melanoma growth or viral infection. In contrast, P14 T cells cultured in IL-15 (P14IL-15) were highly effective in vivo although they displayed only moderate effector functions in vitro. Therapeutic efficacy correlated with the survival of the transferred T cells in the recipients: P14IL-2 cells disappeared rapidly whereas P14IL-15 cells persisted for prolonged time. Decreasing the IL-2 concentration in the culture media improved in vivo survival and efficacy but also lowered the cell yield of the cultures. Finally, we could extend the findings with monoclonal P14 T cells to polyclonal CD8 T cells. Thus, in vitro expansion of antigen-specific CD8 T cells in IL-15 allowed the generation of substantial numbers of T cells without inducing terminally differentiated effector cells that turned out to be unfavorable in the transfer model examined here.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18825743     DOI: 10.1002/eji.200838426

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  21 in total

Review 1.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

Review 2.  CAR-T Cell Therapy for Lymphoma.

Authors:  Carlos A Ramos; Helen E Heslop; Malcolm K Brenner
Journal:  Annu Rev Med       Date:  2015-08-26       Impact factor: 13.739

3.  Induction of tolerance to bone marrow allografts by donor-derived host nonreactive ex vivo-induced central memory CD8 T cells.

Authors:  Eran Ophir; Yaki Eidelstein; Ran Afik; Esther Bachar-Lustig; Yair Reisner
Journal:  Blood       Date:  2009-12-30       Impact factor: 22.113

4.  Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.

Authors:  Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Douglas C Palmer; Luca Gattinoni; Nicholas P Restifo
Journal:  Blood       Date:  2009-06-26       Impact factor: 22.113

5.  The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.

Authors:  N Or-Geva; Y Reisner
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 6.  Chemotherapy and immunotherapy: A close interplay to fight cancer?

Authors:  Aurélie Hanoteau; Muriel Moser
Journal:  Oncoimmunology       Date:  2016-06-21       Impact factor: 8.110

Review 7.  Functions of IL-15 in anti-viral immunity: multiplicity and variety.

Authors:  Katherine C Verbist; Kimberly D Klonowski
Journal:  Cytokine       Date:  2012-06-15       Impact factor: 3.861

Review 8.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  Role of interferon-γ and cytotoxic T lymphocytes in intraocular tumor rejection.

Authors:  Ann J Ligocki; Joseph R Brown; Jerry Y Niederkorn
Journal:  J Leukoc Biol       Date:  2015-11-17       Impact factor: 4.962

10.  Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits.

Authors:  Jia Liu; Sonia Wennier; Mary Reinhard; Edward Roy; Amy MacNeill; Grant McFadden
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.